Kunena :: Тема: Posted by Rousseau on 30.11.2016 9:10:28: erlotinib kinase (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Rousseau on 30.11.2016 9:10:28: erlotinib kinase

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Rousseau on 30.11.2016 9:10:28: erlotinib kinase

Страница:
1
2

ТЕМА: Posted by Rousseau on 30.11.2016 9:10:28: erlotinib kinase

Posted by Rousseau on 30.11.2016 9:10:28: erlotinib kinase 7 года 5 мес. назад #934

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
On May 14, 2013, the U. S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc.) for the first-line treatment of. www.fda.gov/Drugs/InformationOnDrugs/App...dDrugs/ucm352317.htm
Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
gtpartner.by/index.php/component/kunena/...ow-much-tarceva-cost
One thought is someone could wait until there is a 3rd generation EGFR tki available before stopping treatment for a close watch and see. That way there will be a good alternative if tarceva didn’t work if you needed it. On a personal note this is what happened to my husband and he was one in over a hundred or more who hasn’t recurred. He been off treatment for 3 years and NED for almost 4. Also his treatment side effects were becoming increasingly difficult to maintain.
erlotinib oral and grapefruit formula oral
Tarceva, Clinical Trials by Zone, 2014
Tarceva Safety Information
Chemotherapeutic regimens containing 5-fluorouracil (5-FU) and irinotecan are associated with an 80% rate of CID (Robinson & Dobish, 2007). Of those experiencing CID, greater than 30% will experience interference in their daily activities, require hospitalization and risk cardiovascular compromise (Stein, Voigt & Jordan, 2010). Other agents known to cause CID are: capecitabine, cisplatin, cyclophosphamide, cytarabine arabinoside, daunorubicin, doxorubicin, docetaxel, methotrexate, oxaliplatin, and paclitaxel. (Richardson & Dobish, 2007). Targeted therapies such as, erlotinib, sorafenib, and cetuximab, may also cause significant CID.
www.avtourist78.ru/forum/9-%D0%92%D0%B0%...management.html#2902
vand 30 de tablete tarceva de 150 mg. expira in noiembrie 2016. au ramas de la mama unui prieten. pret 1.500 pentru 30 buc sau 500 lei pentru 10 bucati. informatii email: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.
La supervivencia se evaluó en la población por intención de tratar a partir de los datos de supervivencia durante el seguimiento, que incluían 551 defunciones. Se presentan los resultados obtenidos en el grupo con la dosis de 100 mg (504 muertes). La proporción de riesgo ( hazard ratio ) ajustada de fallecimiento en el grupo de TARCEVA ® en comparación con el grupo del placebo fue de 0.82 (IC de 95%: 0.69-0.98) (p = 0.028). El porcentaje de los pacientes vivos a los 12 meses fue de 23.8 y 19.4%, respectivamente, en los grupos de TARCEVA ® y placebo. La mediana de supervivencia global fue de 6.4 y 4 meses, respectivamente, en los grupos de TARCEVA ® y placebo.
Tarceva 25 mg filmomhulde tabletten Tarceva 100 mg filmomhulde tabletten Tarceva 150 mg filmomhulde tabletten Erlotinib
Five of these patients were evaluable for additional therapy, and all were found to be sensitive to further treatment with erlotinib, Dr. Neal reported.
Interacción con otros medicamentos y otras formas de interacción: En el ser humano, el erlotinib lo metabolizan en el hígado por los citocromos hepáticos, principalmente el CYP3A4 y en menor medida el CYP1A2, y la isoforma pulmonar CYP1A1. Potencialmente son posibles interacciones con medicamentos metabolizados por estas enzimas o que sean inhibidores o inductores de las mismas.
Popolazione pediatrica . la sicurezza e l’efficacia di erlotinib in pazienti di età inferiore a 18 anni non sono state stabilite. Non è raccomandato l’impiego di Tarceva in pazienti pediatrici.
La durata mediana della risposta è stata di 34,3 settimane, con un minimo di 9,7 e un massimo di 57,6+ settimane. Il 44,0 % dei pazienti ha ottenuto una risposta completa, parziale o una stabilizzazione della malattia nel gruppo Tarceva, rispetto al 27,5 % dei pazienti nel gruppo placebo (p = 0,004).
biz.fksavoya.ru/index.php/forum/razdel-p...e-cancer-de-pancreas
There is evidence to support safe administration of gefitinib in patients with renal impairment and even haemodialysis. 6,10 However, we highlight the need for caution in patients with predisposing renal risk factors. Switching to erlotinib has been successful in case of more common gefitinib-related adverse events such as hepatotoxicity, pneumonitis and severe neutropenia, 11 but it is not known if this is a safe strategy in the event of acute kidney failure.
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] [abstract 1]. J Clin Oncol 2005 ; 23. 15.
www.goldenkey.me/component/kunena/?func=...catid=5&id=2161#2161
This is an open label, non-randomized, sequential, phase I/II trial in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) with EGFR mutations after progression to Erlotinib. The study will have two parts. The first part (phase I) will be a dose finding (MTD) study to be implemented at three hospitals. The second part of the study (phase II) will asses the safety and efficacy of the combination. In this second part (phase II) patients will be treated with oral Erlotinib 150 mg P.O daily plus oral Vorinostat administered according to the results of the phase I. The study endpoints to be evaluated will include safety and response rate (RR) as primary endpoints and clinical benefit rate (CBR), time to progression, time to response, response duration and progression free survival as secondary endpoints. All the patients (phase I and II) will be treated until progression disease, unacceptable toxicity or withdrawal of the consent, and will be treated at the discretion of the principal investigator.
Composite pharmacokinetics of erlotinib in the presence of INC280.
Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial
ansb.ru/kunena/dobro-pozhalovat/25843-po...de-side-effects.html
European Medicines Agency. Tarceva. Summary of Product Characteristics, 3 February 2014. Accessed at www.ema.europa.eu/docs/en_GB/document_li...0618/WC500033994.pdf. [20 Feb 2014].
Experimental: Treatment (erlotinib hydrochloride, selumetinib)
Wash your hands immediately after taking erlotinib.
petersburglife.ru/index.php?option=com_f...catid=5&id=6430#6430
Thank you for keeping us updated. My mum has just started on tarceva so this has been helpfull. Hope your husband gets a break from the rash soon. Nicky.
I think it’s more likely because all these drugs are being tested for their own efficacy. Usually when drugs are combined it’s known what one of the drugs will probably do. When tarceva is paired it’s being tested on those who are EGFR positive. PD1 is being tested in a broader class of people.
maz68.ru/index.php/forum?func=view&catid=3&id=9475
In vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver. Therefore, erlotinib exposure may be increased in patients with hepatic dysfunction (see CLINICAL PHARMACOLOGY - Special Populations - Patients with Hepatic Impairment and DOSAGE AND ADMINISTRATION - Dose Modifications sections).
Tarceva tags categories:
* Recent work at Cold Spring Harbor Laboratory indicates that “half” of the cases of Tarceva resistance is driven by “secondary mutations within” Epidermal Growth Factor Receptor (EGFR; ErbB-1; HER1) “or amplification of c-Met proto-oncogene (MET; HGFR).”[3].
Erlotinib (Tarceva) targets the epidermal growth factor receptor (EGFR), which is commonly overexpressed in human cancers, including lung cancer. We show that erlotinib can be labeled with [(11)C] by reacting the normethyl precursor with [(11)C]-methyl iodide. By using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide proliferation assay, two lung cancer cell lines (A549 and NCI358) were shown to be less sensitive to erlotinib compared with the lung cancer cell line HCC827. This correlated with higher expression and activity of the EGFR in HCC827 cells as compared with the less sensitive cell lines. Micro-positron emission tomography (PET) and biodistribution of erlotinib was performed with [(11)C]-erlotinib in nude mice bearing xenografts of A549, NCI358, and HCC827 cells. Dynamic micro-PET showed that HCC827 tumors had the highest [(11)C]-erlotinib uptake and retained the activity significantly longer as compared with A549 and NCI358 tumors. Biodistribution of [(11)C]-erlotinib in the xenograft models of lung cancer showed the highest accumulation in the liver. In mice carrying the sensitive cancer cells, the accumulation of [(11)C]-erlotinib was higher in tumors than in the other organs. In contrast, the drug accumulated to a comparable extent in tumors from the less sensitive cancer cells and the other organs. Uptake of [(11)C]-erlotinib in the tumors was 1.6%, 0.7%, and 3.7% (percentage of injected dose/g), in A549, NCI358, and HCC827 cells, respectively. We show for the first time that [(11)C]-erlotinib identifies erlotinib-sensitive tumors. These results pave the road for studies examining the benefit of [(11)C]-erlotinib PET in patients with lung tumors or other tumors overexpressing EGFR.
Comparative Example 16: Reproduction of the process described in US5747498 for the preparation of erlotinib hydrochloride from 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline